Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: Retrospective analysis of real-world data

Cancer Medicine

Volumn 5, Issue 2, 2016, Pages 182-191

  Flaig, Thomas W ^a   Potluri, Ravi C ^b   Ng, Yvette ^c   Todd, Mary B ^c   Mehra, Maneesha ^c  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b SmartAnalyst   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Metastatic castration resistant prostate cancer; Prostate cancer; Real world; Treatment patterns

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; MITOXANTRONE; NEW DRUG; PRESCRIPTION DRUG; RADIUM; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; ELECTRONIC MEDICAL RECORD; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES; FACTUAL DATABASE; HEALTH SURVEY; HISTORY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DATABASES, FACTUAL; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 85006190441     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.576     Document Type: Article

References (30)

1. Garnick, M. B., L. M. Glode, J. A. Jr Smith, and D. T. Max 1985. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate. Br. J. Clin. Pract. 39:73-76.
2. Oudard, S. 2013. Progress in emerging therapies for advanced prostate cancer. Cancer Treat. Rev. 39:275-289.
3. Lam, J. S., J. T. Leppert, S. N. Vemulapalli, O. Shvarts, and A. S. Belldegrun 2006. Secondary hormonal therapy for advanced prostate cancer. J. Urol. 175:27-34.
4. Tannock, I. F., D. Osoba, M. R. Stockler, D. S. Ernst, A. J. Neville, M. J. Moore, et al. 1996. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14:1756-1764.
5. Petrylak, D. P., C. M. Tangen, M. H. Hussain, P. N. Lara Jr, J. A. Jones, M. E. Taplin, et al. 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351:1513-1520.
6. Tannock, I. F., R. de Wit, W. R. Berry, J. Horti, A. Pluzanska, K. N. Chi, et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351:1502-1512.
7. Harris, V., K. Lloyd, S. Forsey, P. Rogers, M. Roche, and C. Parker 2011. A population-based study of prostate cancer chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 23:706-708.
8. Droz, J. P., M. Aapro, L. Balducci, H. Boyle, T. Van den Broeck, P. Cathcart, et al. 2014. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 15:e404-e414.
9. Fizazi, K. S., C. S. Higano, J. B. Nelson, M. Gleave, K. Miller, and T. Morris 2013. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 31:1740-1747.
10. Tannock, I. F., K. Fizazi, S. Ivanov, C. T. Karlsson, A. Flechon, I. Skoneczna, et al. 2013. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 14:760-768.
11. Cookson, M. S., B. J. Roth, P. Dahm, C. Engstrom, S. J. Freedland, M. Hussain, et al. 2013. Castration-resistant prostate cancer: AUA Guideline. J. Urol. 190:429-438.
12. Kantoff, P. W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363:411-422.
13. de Bono, J. S., S. Oudard, M. Ozguroglu, S. Hansen, J. P. Machiels, I. Kocak, et al. 2010. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154.
14. Parker, C., S. Nilsson, D. Heinrich, S. I. Helle, J. M. O'Sullivan, S. D. Fossa, et al. 2013. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369:213-223.
15. Montgomery, R. B., E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. Kalhorn, C. S. Higano, et al. 2008. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68:4447-4454.
16. O'Donnell, A., I. Judson, M. Dowsett, F. Raynaud, D. Dearnaley, M. Mason, et al. 2004. Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90:2317-2325.
17. Tran, C., S. Ouk, N. J. Clegg, Y. Chen, P. A. Watson, V. Arora, et al. 2009. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790.
18. Lissbrant, I. F., H. Garmo, A. Widmark, and P. Stattin 2013. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 52:1593-1601.
19. de Bono, J. S., C. J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364:1995-2005.
20. Scher, H. I., K. Fizazi, F. Saad, M. E. Taplin, C. N. Sternberg, K. Miller, et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367:1187-1197.
21. Rathkopf, D. E., M. R. Smith, J. S. de Bono, C. J. Logothetis, N. D. Shore, P. de Souza, et al. 2014. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. 66:815-825.
22. Shelke, A. R., and S. G. Mohile 2011. Treating prostate cancer in elderly men: how does aging affect the outcome? Curr. Treat. Options Oncol. 12:263-275.
23. Mulders, P. F., A. Molina, M. Marberger, F. Saad, C. S. Higano, K. N. Chi, et al. 2013. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur. Urol. 65:875-883.
24. Mukherji, D., C. J. Pezaro, A. Shamseddine, and J. S. de Bono 2013. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat. Rev. 39:578-583.
25. Fritz, J. M., and J. Cleland 2003. Effectiveness versus efficacy: more than a debate over language. J. Orthop. Sports Phys. Ther. 33:163-165.
26. Revicki, D. A., and L. Frank 1999. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 15:423-434.
27. Fizazi, K., H. I. Scher, A. Molina, C. J. Logothetis, K. N. Chi, R. J. Jones, et al. 2012. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13:983-992.
28. Ryan, C. J., M. R. Smith, J. S. de Bono, A. Molina, C. J. Logothetis, P. de Souza, et al. 2013. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368:138-148.
29. Beer, T. M., A. J. Armstrong, D. E. Rathkopf, Y. Loriot, C. N. Sternberg, C. S. Higano, et al. 2014. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371:424-433.
30. ®): Prostate Cancer: Version 1. National Comprehensive Cancer Network Web site 2015 November 10; Available at www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. (accessed 30 November 2015).